Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles and rubella vaccine, live
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The measles and rubella vaccine (live), specifically the combination of the Schwarz FF-8 measles strain and the TO-336 rubella strain, is a live attenuated biologic developed by Takeda Pharmaceutical for active immunization against measles and rubella. Marketed in Japan under the brand name Takeda, this freeze-dried vaccine is reconstituted for subcutaneous administration. The Schwarz FF-8 strain is a further attenuated variant of the Schwarz measles strain, while the TO-336 strain is a rubella vaccine strain primarily utilized in the Japanese market. The vaccine works by inducing a protective immune response, including the production of neutralizing antibodies and cellular immunity, against both the measles morbillivirus and the rubella virus.
- Brand names
- Freeze-dried Live Attenuated Measles and Rubella Combined Vaccine Takeda
- Other names
- measles virus vaccine live attenuated (Schwarz FF-8 strain) + rubella virus vaccine live attenuated (TO-336 strain)MR vaccine TakedaSchwarz FF-8 strain/TO-336 strain vaccine
Beyond the preview
Go deeper on measles and rubella vaccine, live.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles and rubella vaccine, live.